Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sucampo Pharma Inc (SCMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 849,060
  • Shares Outstanding, K 47,170
  • Annual Sales, $ 230,060 K
  • Annual Income, $ 18,490 K
  • 36-Month Beta 1.38
  • Price/Sales 3.25
  • Price/Cash Flow 7.47
  • Price/Book 21.18
  • Price/Earnings ttm 12.33
  • Earnings Per Share ttm 1.46
  • Most Recent Earnings 0.27 on 11/01/17
  • Next Earnings Date 03/14/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate 0.34
  • Number of Estimates 3
  • High Estimate 0.36
  • Low Estimate 0.32
  • Prior Year 0.68
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.85 +1.12%
on 01/24/18
18.30 -1.37%
on 01/17/18
unch (unch)
since 01/12/18
3-Month
10.10 +78.71%
on 11/16/17
18.75 -3.73%
on 01/08/18
+7.75 (+75.24%)
since 11/13/17
52-Week
9.30 +94.09%
on 04/18/17
18.75 -3.73%
on 01/08/18
+6.55 (+56.96%)
since 02/13/17

Most Recent Stories

More News
Uptrend Call Working As Sucampo Pha-Cl A Stock Rises 61.1% (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 10 months, Sucampo Pha-Cl A has returned 61.07% as of today's recent price of $18.00....

SCMP : 18.05 (+0.28%)
Uptrend Call Working As Sucampo Pha-Cl A Stock Rises 61.1% (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 9 months, Sucampo Pha-Cl A has returned 61.07% as of today's recent price of $18.00....

SCMP : 18.05 (+0.28%)
61.1% Return Seen to Date on SmarTrend Sucampo Pha-Cl A Call (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 9 months, Sucampo Pha-Cl A has returned 61.07% as of today's recent price of $18.00....

SCMP : 18.05 (+0.28%)
Uptrend Call Working As Sucampo Pha-Cl A Stock Rises 61.1% (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 9 months, Sucampo Pha-Cl A has returned 61.07% as of today's recent price of $18.00....

SCMP : 18.05 (+0.28%)
Global Irritable Bowel Syndrome Treatment Market Analysis By Top Players, Size, Share Forecasting UpTo 2026

VRX.TO : 30.80 (-3.33%)
ABT : 69.05 (+0.38%)
IRWD : 17.17 (-0.75%)
SCMP : 18.05 (+0.28%)
TKPYY : 20.9550 (-0.97%)
SGYP : 1.69 (-1.74%)
GSK : 40.30 (+1.08%)
Imara Announces Appointment of Kevin B. Johnson, Ph.D., MBA, as Senior Vice President of Regulatory and Quality

Imara Inc., a clinical stage biopharmaceutical company, today announced that Kevin B. Johnson, Ph.D., MBA, has been appointed Senior Vice President of Regulatory and Quality. Dr. Johnson...

SCMP : 18.05 (+0.28%)
Sucampo Pha-Cl A Up 61.1% Since SmarTrend Uptrend Call (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 8 months, Sucampo Pha-Cl A has returned 61.07% as of today's recent price of $18.00....

SCMP : 18.05 (+0.28%)
Global Irritable Bowel Syndrome Treatment Market Analysis By Technological Advancement, Regional Outlook And Forecast to 2026

The new research from on Global Irritable Bowel Syndrome Treatment Market Report for 2018 destined to provide target audience with the latest information on with the help of refined data and opinions...

VRX.TO : 30.80 (-3.33%)
ABT : 69.05 (+0.38%)
SCMP : 18.05 (+0.28%)
ALPMF : 17.7400 (+4.97%)
NVS : 85.46 (-0.59%)
TKPYY : 20.9550 (-0.97%)
SGYP : 1.69 (-1.74%)
GSK : 40.30 (+1.08%)
Look for Shares of Gartner Inc to Potentially Pullback after Yesterday's 1.60% Rise

Gartner Inc (NYSE:IT) traded in a range yesterday that spanned from a low of $134.09 to a high of $135.70. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $134.69...

SCMP : 18.05 (+0.28%)
IT : 158.45 (+0.98%)
Uptrend Call Working As Sucampo Pha-Cl A Stock Rises 61.1% (SCMP)

SmarTrend identified an Uptrend for Sucampo Pha-Cl A (NASDAQ:SCMP) on November 28th, 2017 at $11.18. In approximately 7 months, Sucampo Pha-Cl A has returned 61.07% as of today's recent price of $18.00....

SCMP : 18.05 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade SCMP with:

Business Summary

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical...

See More

Key Turning Points

2nd Resistance Point 18.14
1st Resistance Point 18.07
Last Price 18.05
1st Support Level 17.94
2nd Support Level 17.88

See More

52-Week High 18.75
Last Price 18.05
Fibonacci 61.8% 15.14
Fibonacci 50% 14.02
Fibonacci 38.2% 12.91
52-Week Low 9.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar